Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Axsome TherapeuticsCytoDynDeciphera PharmaceuticalsPrelude TherapeuticsGlobal Blood Therapeutics
SymbolNASDAQ:AXSMOTCMKTS:CYDYNASDAQ:DCPHNASDAQ:PRLDNASDAQ:GBT
Price Information
Current Price$52.99$3.13$43.81$35.26$40.77
52 Week RangeBuyHoldBuyHoldBuy
MarketRank™
Overall Score1.41.11.61.41.4
Analysis Score3.43.03.43.13.4
Community Score2.72.62.51.73.0
Dividend Score0.00.00.00.00.0
Ownership Score0.80.01.71.70.0
Earnings & Valuation Score0.00.00.60.60.6
Analyst Ratings
Consensus RecommendationBuyHoldBuyHoldBuy
Consensus Price Target$146.90$4.00$70.30$54.25$92.33
% Upside from Price Target177.22% upside27.80% upside60.47% upside53.86% upside126.47% upside
Trade Information
Market Cap$1.98 billion$1.92 billion$2.52 billion$1.64 billion$2.53 billion
Beta2.59-0.641.49N/A1.39
Average Volume304,0244,818,552442,447219,338996,688
Sales & Book Value
Annual RevenueN/AN/A$25 millionN/A$2.11 million
Price / SalesN/AN/A100.98N/A1,201.01
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$5.18 per share($0.01) per share$10.71 per shareN/A$9.61 per share
Price / BookN/AN/A4.09N/A4.24
Profitability
Net Income$-68,350,000.00$-124,400,000.00$-192,260,000.00N/A$-266,770,000.00
EPS($2.01)($0.21)($4.48)N/A($4.71)
Trailing P/E RatioN/AN/AN/A0.00N/A
Forward P/E RatioN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/AN/A-332.94%
Return on Equity (ROE)-62.33%N/A-45.02%N/A-56.43%
Return on Assets (ROA)-47.87%-153.30%-40.12%N/A-39.32%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.36%5.01%N/AN/A0.16%
Current Ratio9.99%1.13%9.34%20.96%7.63%
Quick Ratio9.99%0.28%9.26%20.96%7.20%
Ownership Information
Institutional Ownership Percentage63.64%0.10%73.61%76.21%N/A
Insider Ownership Percentage26.00%7.80%7.02%N/A4.30%
Miscellaneous
Employees601925568389
Shares Outstanding37.41 million612.83 million57.63 million46.59 million62.16 million
Next Earnings Date5/14/2021 (Estimated)N/A5/4/2021 (Estimated)6/15/2021 (Estimated)5/5/2021 (Estimated)
OptionableOptionableNot OptionableOptionableNot OptionableOptionable
SourceHeadline
Shareholders Are Thrilled That The Global Blood Therapeutics (NASDAQ:GBT) Share Price Increased 101%Shareholders Are Thrilled That The Global Blood Therapeutics (NASDAQ:GBT) Share Price Increased 101%
finance.yahoo.com - April 9 at 8:50 AM
Global Blood Therapeutics Sickle Cell Med Results In Rapid, Durable Improvements In Hemoglobin Levels Throughout 72 Weeks Of TreatmentGlobal Blood Therapeutics' Sickle Cell Med Results In Rapid, Durable Improvements In Hemoglobin Levels Throughout 72 Weeks Of Treatment
finance.yahoo.com - April 8 at 2:03 PM
Complete 72-Week Results from Phase 3 HOPE Study of Oxbryta® (voxelotor) Tablets Published in The Lancet Haematology Show Significantly Improved Hemoglobin, Hemolysis and Overall Health Status in Sickle Cell Disease PatientsComplete 72-Week Results from Phase 3 HOPE Study of Oxbryta® (voxelotor) Tablets Published in The Lancet Haematology Show Significantly Improved Hemoglobin, Hemolysis and Overall Health Status in Sickle Cell Disease Patients
finance.yahoo.com - April 8 at 9:03 AM
$43.24 Million in Sales Expected for Global Blood Therapeutics, Inc. (NASDAQ:GBT) This Quarter$43.24 Million in Sales Expected for Global Blood Therapeutics, Inc. (NASDAQ:GBT) This Quarter
americanbankingnews.com - April 8 at 4:02 AM
Global Blood Therapeutics (NASDAQ:GBT) Upgraded to Hold by Zacks Investment ResearchGlobal Blood Therapeutics (NASDAQ:GBT) Upgraded to Hold by Zacks Investment Research
marketbeat.com - April 6 at 2:08 PM
Financial Comparison: Dr. Reddys Laboratories (NYSE:RDY) versus Global Blood Therapeutics (NASDAQ:GBT)Financial Comparison: Dr. Reddy's Laboratories (NYSE:RDY) versus Global Blood Therapeutics (NASDAQ:GBT)
americanbankingnews.com - April 4 at 12:10 PM
Global Blood Therapeutics: Can This Biotech Still Disrupt The Sickle Cell Disease Space?Global Blood Therapeutics: Can This Biotech Still Disrupt The Sickle Cell Disease Space?
finance.yahoo.com - April 4 at 8:39 AM
Global Blood Therapeutics, Inc. (NASDAQ:GBT) Given Average Recommendation of "Buy" by AnalystsGlobal Blood Therapeutics, Inc. (NASDAQ:GBT) Given Average Recommendation of "Buy" by Analysts
americanbankingnews.com - April 1 at 12:52 PM
Global Blood (GBT) Down 7.1% Since Last Earnings Report: Can It Rebound?Global Blood (GBT) Down 7.1% Since Last Earnings Report: Can It Rebound?
finance.yahoo.com - March 26 at 3:10 PM
Newron Pharmaceuticals (OTCMKTS:NWPHF) versus Global Blood Therapeutics (NASDAQ:GBT) Head-To-Head ComparisonNewron Pharmaceuticals (OTCMKTS:NWPHF) versus Global Blood Therapeutics (NASDAQ:GBT) Head-To-Head Comparison
americanbankingnews.com - March 24 at 4:54 AM
GBT Appoints Alexis A. Thompson, M.D., M.P.H., to Board of DirectorsGBT Appoints Alexis A. Thompson, M.D., M.P.H., to Board of Directors
finance.yahoo.com - March 18 at 8:25 AM
Analysts Offer Insights on Healthcare Companies: Global Blood Therapeutics (GBT), Aprea Therapeutics (APRE) and Nabriva (NBRV)Analysts Offer Insights on Healthcare Companies: Global Blood Therapeutics (GBT), Aprea Therapeutics (APRE) and Nabriva (NBRV)
smarteranalyst.com - March 17 at 12:08 PM
Wolfe Research Initiates Coverage on Global Blood Therapeutics (NASDAQ:GBT)Wolfe Research Initiates Coverage on Global Blood Therapeutics (NASDAQ:GBT)
americanbankingnews.com - March 17 at 11:35 AM
Wolfe Research Begins Coverage on Global Blood Therapeutics (NASDAQ:GBT)Wolfe Research Begins Coverage on Global Blood Therapeutics (NASDAQ:GBT)
marketbeat.com - March 17 at 8:35 AM
Global Blood Therapeutics inks deal for two sickle cell disease drugs from SanofiGlobal Blood Therapeutics inks deal for two sickle cell disease drugs from Sanofi
medcitynews.com - March 16 at 9:06 PM
GBT Expands Sickle Cell Disease Pipeline with Exclusive In-license of Two Novel Small Molecule Programs from Sanofi S.A.GBT Expands Sickle Cell Disease Pipeline with Exclusive In-license of Two Novel Small Molecule Programs from Sanofi S.A.
finance.yahoo.com - March 16 at 11:05 AM
GBT Announces Participation at the H.C. Wainwright Global Life Sciences ConferenceGBT Announces Participation at the H.C. Wainwright Global Life Sciences Conference
finance.yahoo.com - March 2 at 11:39 AM
GBT Opens 2021 ACCEL Grant Program, Providing up to $500,000 in Support to the Sickle Cell Disease CommunityGBT Opens 2021 ACCEL Grant Program, Providing up to $500,000 in Support to the Sickle Cell Disease Community
finance.yahoo.com - March 2 at 11:39 AM
Black History and Biotechnology: A Conversation with Dr. Ted Love, President and CEO of Global Blood Therapeutics (GBT)Black History and Biotechnology: A Conversation with Dr. Ted Love, President and CEO of Global Blood Therapeutics (GBT)
bio.org - February 25 at 8:56 PM
Global Blood (GBT) Q4 Earnings Miss, Revenues Beat EstimatesGlobal Blood (GBT) Q4 Earnings Miss, Revenues Beat Estimates
nasdaq.com - February 25 at 3:56 PM
Recap: Global Blood Therapeutics Q4 EarningsRecap: Global Blood Therapeutics Q4 Earnings
finance.yahoo.com - February 25 at 12:11 AM
GBT Reports Recent Business Progress and Fourth Quarter and Full Year 2020 Financial ResultsGBT Reports Recent Business Progress and Fourth Quarter and Full Year 2020 Financial Results
finance.yahoo.com - February 24 at 7:11 PM
Preview: Global Blood Therapeuticss EarningsPreview: Global Blood Therapeutics's Earnings
finance.yahoo.com - February 23 at 2:21 PM
Global Blood Therapeutics (GBT) May Report Negative Earnings: Know the Trend Ahead of Q4 ReleaseGlobal Blood Therapeutics (GBT) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
markets.businessinsider.com - February 18 at 8:14 AM
GBT to Announce Fourth Quarter and Full Year 2020 Financial Results on Wednesday, February 24, 2021GBT to Announce Fourth Quarter and Full Year 2020 Financial Results on Wednesday, February 24, 2021
finance.yahoo.com - February 17 at 12:00 PM
Is Global Blood Therapeutics (NASDAQ:GBT) A Risky Investment?Is Global Blood Therapeutics (NASDAQ:GBT) A Risky Investment?
finance.yahoo.com - February 8 at 9:08 AM
GBT Initiates Expanded Access Protocol for Oxbryta(R) (voxelotor) in Pediatric Patients with Sickle Cell Disease in the United StatesGBT Initiates Expanded Access Protocol for Oxbryta(R) (voxelotor) in Pediatric Patients with Sickle Cell Disease in the United States
marketwatch.com - February 5 at 9:57 AM
DateCompanyBrokerageAction
3/8/2021Axsome TherapeuticsMorgan StanleyBoost Price Target
3/2/2021Axsome TherapeuticsMizuhoLower Price Target
1/8/2021Axsome TherapeuticsJefferies Financial GroupInitiated Coverage
12/31/2020Axsome TherapeuticsUBS GroupReiterated Rating
12/3/2020Axsome TherapeuticsCantor FitzgeraldBoost Price Target
10/1/2020Axsome TherapeuticsWilliam BlairReiterated Rating
9/29/2020Axsome TherapeuticsBank of AmericaInitiated Coverage
8/6/2020Axsome TherapeuticsHC WainwrightReiterated Rating
4/28/2020Axsome TherapeuticsGuggenheimBoost Price Target
4/27/2020Axsome TherapeuticsLADENBURG THALM/SH SHBoost Price Target
4/27/2020Axsome TherapeuticsSunTrust BanksBoost Price Target
4/14/2020Axsome TherapeuticsCowenInitiated Coverage
3/30/2021Deciphera PharmaceuticalsCredit Suisse GroupInitiated Coverage
2/10/2021Deciphera PharmaceuticalsBarclaysLower Price Target
2/10/2021Deciphera PharmaceuticalsSVB LeerinkUpgrade
12/2/2020Deciphera PharmaceuticalsStifel NicolausInitiated Coverage
9/14/2020Deciphera PharmaceuticalsJPMorgan Chase & Co.Initiated Coverage
5/7/2020Deciphera PharmaceuticalsNomura InstinetDowngrade
1/22/2020Deciphera PharmaceuticalsPiper SandlerReiterated Rating
1/21/2020Deciphera PharmaceuticalsNomura SecuritiesBoost Price Target
1/15/2020Deciphera PharmaceuticalsJMP SecuritiesReiterated Rating
12/20/2019Deciphera PharmaceuticalsPiper Jaffray CompaniesBoost Price Target
10/20/2020Prelude TherapeuticsThe Goldman Sachs GroupInitiated Coverage
3/17/2021Global Blood TherapeuticsWolfe ResearchInitiated Coverage
12/3/2020Global Blood TherapeuticsRoyal Bank of CanadaInitiated Coverage
11/9/2020Global Blood TherapeuticsTruistLower Price Target
11/6/2020Global Blood TherapeuticsCanaccord GenuityLower Price Target
11/6/2020Global Blood TherapeuticsRoth CapitalLower Price Target
11/6/2020Global Blood TherapeuticsOppenheimerLower Price Target
11/6/2020Global Blood TherapeuticsRaymond JamesDowngrade
10/6/2020Global Blood TherapeuticsEvercore ISIInitiated Coverage
8/25/2020Global Blood TherapeuticsWedbushBoost Price Target
(Data available from 4/10/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.